J 2024

Ex-vivo 3D cellular models of pancreatic ductal adenocarcinoma: from embryonic development to precision oncology

AĆIMOVIĆ, Ivana, Viktorie GABRIELOVÁ, Stanislava MARTÍNKOVÁ, Michal EID, Jakub VLAŽNÝ et. al.

Basic information

Original name

Ex-vivo 3D cellular models of pancreatic ductal adenocarcinoma: from embryonic development to precision oncology

Authors

AĆIMOVIĆ, Ivana, Viktorie GABRIELOVÁ, Stanislava MARTÍNKOVÁ, Michal EID, Jakub VLAŽNÝ, Petr MORAVČÍK, Jan HLAVSA, Lukáš MORÁŇ, Riza Can CAKMAKCI, Peter STAŇO, Vladimír PROCHÁZKA, Zdeněk KALA, Jan TRNKA and Petr VAŇHARA

Edition

PANCREAS, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2024, 0885-3177

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30400 3.4 Medical biotechnology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.900 in 2022

Organization unit

Faculty of Medicine

UT WoS

999

Tags

International impact, Reviewed
Změněno: 19/8/2024 13:00, Mgr. Tereza Miškechová

Abstract

V originále

Pancreas is a vital gland of gastro-intestinal system with exocrine and endocrine secretory functions, interweaved into essential metabolic circuitries of the human body. Pancreatic ductal adenocarcinoma (PDAC) represents one of the most lethal malignancies, with a five-year survival rate of 11%. This poor prognosis is primarily attributed to the absence of early symptoms, rapid metastatic dissemination, and the limited efficacy of current therapeutic interventions. Despite recent advancements in understanding the etiopathogenesis and treatment of PDAC, there remains a pressing need for improved individualized models, the identification of novel molecular targets, and the development of unbiased predictors of disease progression. Here we aim to explore the concept of precision medicine utilizing three-dimensional, patient-specific cellular models of pancreatic tumors and discuss their potential applications in uncovering novel druggable molecular targets and predicting clinical parameters for individual patients.

Links

MUNI/A/1558/2023, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit XI
Investor: Masaryk University
MUNI/A/1598/2023, interní kód MU
Name: Zdroje pro tkáňové inženýrství 14
Investor: Masaryk University, Resources pro tissue engineering 14
NU23-08-00241, research and development project
Name: Vývoj ex-vivo buněčných modelů pro adenokarcinom pankreatu: markery a cíle pro precizní medicínu
Investor: Ministry of Health of the CR, Development of ex vivo cellular models for pancreatic adenocarcinoma: markers and targets for precision medicine, Subprogram 1 - standard